I. Introduction
===============

Among several bone substitutes that are used for craniofacial reconstruction, the known properties of alloplastic materials including no donor site morbidity, less operation time and complexity, and less probability of cross infection, transcend the disadvantages of autograft, allograft, and xenograft[@B1][@B2][@B3]. Calcium phosphate-based materials are analogous to inorganic bone matrix[@B4]. Innovations in their cement form overcome the shortage of their ceramic form; because of osteoconductivity, good moldability, and structural stability, they are widely used for craniofacial defects[@B5][@B6][@B7][@B8]. Although several studies indicate the biocompatibility of calcium phosphate-based materials[@B9][@B10][@B11], there are reports of foreign body reaction and seroma collection after craniofacial reconstruction using different cements such as Norian CRS (Synthes-Stratec, Oberdorf, Switzerland), Mimix (Walter Lorenz Surgical, Jacksonville, FL, USA), and Bone Source (Stryker Leibinger, Freiburg, Germany)[@B12][@B13][@B14][@B15][@B16]. We report a patient who showed foreign body reaction following use of JectOS, an injectable calcium orthophosphate cement (Kasios, Launaguet, France), for reconstruction of a frontal bone defect. We also reviewed literature from 2002 to 2017 that reported complications of calcium phosphate cements after craniofacial reconstruction[@B12][@B13][@B14][@B15][@B16][@B17][@B18][@B19][@B20][@B21][@B22][@B23][@B24][@B25][@B26].([Table 1](#T1){ref-type="table"})

Search terms of craniofacial, frontal, complication, and calcium phosphate cement were submitted to ScienceDirect, PubMed, and Google Scholar databases. Only English articles that reported complications after craniofacial reconstruction with this material were included.

To the best of our knowledge, no adverse effects of JectOS were published following craniofacial application.

II. Case Report
===============

A 28-year-old woman was referred to the Oral and Maxillofacial unit of Taleghani Hospital (Tehran, Iran) in 2010 because of multiple facial fractures. Physical examination and radiographic study revealed bilateral naso-orbito-ethmoid and zygomaticomaxillary complex fractures and fracture of anterior and posterior tables of the frontal sinus with displacement. The naso-frontal duct was intact, and there was no cerebrospinal fluid outflow. The patient underwent open reduction and rigid internal fixation of the complex fractures and reconstruction of the frontal anterior table with titanium mesh and JectOS.([Fig. 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}) Four months later, the patient presented with a midfrontal fistula.([Fig. 3](#F3){ref-type="fig"}) Exudate culture did not show any bacterial growth, and the patient underwent debridement and fistulectomy. The pathological study showed granulation tissue and giant cells, confirming a foreign body reaction. Nine months later, because the frontal drainage did not stop and several outpatient irrigation and debridement procedures were not successful, debridement and removal of the reconstructive titanium mesh and JectOS were performed, and a calvarial autograft was used to reconstruct the frontal depressed defect. The postoperation course and 6-year follow-up were uneventful.([Fig. 4](#F4){ref-type="fig"})

III. Discussion
===============

From a cosmetic stand point and because of little stress on the craniofacial structure, use of calcium phosphate biomaterials for craniofacial reconstruction is desirable. Currently, two major groups of calcium phosphate cements are available: apatite cements with poorly crystalline hydroxyapatite (HA) and calcium-deficient HA (CDHA), and dicalcium phosphate dihydrate (DCPD) cements, also called brushite, such as B-tricalcium phosphate (B-TCP)[@B4].

Complications after calcium phosphate biomaterial application are divided into two categories: immunologic reactions[@B27] and non-immunologic events such as infection[@B15][@B17], fragmentation, ejection, and migration[@B18][@B19].

According to the literature, proximity of the incision line to the surgical site, wound tension that results in wound dehiscence, previous radiation therapy, and minor trauma at the site of surgery are probable reasons for infection after the use of these materials[@B2][@B12][@B20][@B21][@B24].

Some research reported fragmentation and ejection of calcium phosphate cements contacting the dura and proposed the use of a protective mesh under cement to prevent dura pulse transmission[@B19][@B22].

Zins et al.[@B25][@B28] reported a high rate of complications after reconstruction of a large, full-thickness cranial defect with Bone Source and Norian CRS and suggested the use of autogenous graft for reconstruction of these patients.

Immunologic host reactions following implantation of biomaterials include blood-material interactions and acute or chronic inflammation. Although early resolution of the inflammatory response is expected after application of a biocompatible material, the formation of granulation tissue after chronic inflammation results in a foreign body reaction and fibrous capsule formation[@B27][@B29].

Development of tissue reactions, like persistent swelling and seroma collection or chronic drain fistula, after cranio-facial application of HA or calcium phosphate cements results in surgeons not using these biomaterials in contact with the sinus mucosa[@B12][@B13][@B15][@B23]. This reaction was observed among all ages, and no difference between genders was reported[@B23]. According to these reports, the use of Bone Source, Mimix, or Norian CRS to reconstruct the frontal deepening is not desired, especially if the sinus mucosa is exposed.

JectOS is a calcium orthophosphate cement made up of 55% DCPD and 45% TCP. Uygur et al.[@B30] reported a case of soft tissue necrosis around a lateral malleolar region following the filling of a calcaneus bone cyst with JectOS. On the second and third days postoperative, local pain, burning sensation, erythema, and serous fluid leakage in the injection region resulted in skin and soft tissue necrosis with no evidence of deep infection.

In our experience with JectOS, host reaction symptoms were evident after four months. Multiple outpatient procedures did not stop the chronic discharge; therefore, after nine months, the patient underwent complete graft removal, and no evidence of local infection or fragmentation was observed.

Therefore, the rate of postsurgical failure, including infection, following biomaterial usage, is high due to inadequate blood supply and infection control disturbance. Most of the research describing biomaterial complications report infection as the predominant side effect; however, in this case report, the patient did not suffer from infection. From a management perspective and time to occurrence, this case had more serious complications than other reports.

According to the literature, application of calcium phosphate biomaterials consisting of JectOS on fractured frontal bone in contact with sinus membrane and disrupted blood supply can result in foreign body reaction and infection. Therefore, long-term follow-up after biomaterial application is suggested.
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![Reconstruction of the frontal defect with titanium mesh.](jkaoms-44-207-g001){#F1}

![Coverage of the frontal defect and titanium mesh with JectOS (Kasios).](jkaoms-44-207-g002){#F2}
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![Postoperation course after debridement and removal of the reconstructive titanium mesh and JectOS (Kasios).](jkaoms-44-207-g004){#F4}

###### Frequency of reported complications after craniofacial reconstruction with different calcium-phosphate cements from 2002 to 2017

![](jkaoms-44-207-i001)

  Study (year)                           No. of patients/mean age   Site                          Material                         Mean follow-up   Infection   Seroma collection, chronic sinus   Foreign body reaction   Ejection, fragmentation   Dehiscence   Swelling
  -------------------------------------- -------------------------- ----------------------------- -------------------------------- ---------------- ----------- ---------------------------------- ----------------------- ------------------------- ------------ ----------
  Matic and Phillips[@B12] (2002)        15/6 yr                    Craniofacial                  Bone Source                      NA               2           3                                  3                       \-                        \-           \-
  Baker et al.[@B26] (2002)              16/22.8 yr                 Craniofacial                  Norian CRS                       18.3 mo          1           \-                                 \-                      3                         \-           \-
  Mathur et al.[@B15] (2003)             35/30.4 yr                 Craniofacial                  Norian CRS, Bone Source          NA               6           \-                                 1                       \-                        \-           \-
  Durham et al.[@B17] (2003)             8/12.2 yr                  Cranioplasty                  HA                               11.4 mo          2           \-                                 \-                      \-                        \-           \-
  Eppley et al.[@B16] (2003)             62/11.7 yr                 Cranioplasty                  Mimix                            26 mo            3           \-                                 \-                      \-                        \-           \-
  Magee et al.[@B13] (2004)              48/7.5 yr                  Craniofacial                  Bone Source                      17 mo            2           2                                  \-                      \-                        \-           1
  Gómez et al.[@B20] (2005)              5/4.6 yr                   Craniofacial                  Norian CRS                       14 mo            1           \-                                 \-                      \-                        \-           \-
  Greenberg and Schneider[@B22] (2005)   85/8 yr                    Cranioorbital                 Norian CRS, Mimix, Bone Source   \>3 yr           3           1                                  \-                      1                         \-           \-
  David et al.[@B19] (2005)              8/55 mo                    Cranioplasty                  Bone Source                      38 mo            \-          \-                                 \-                      2                         \-           \-
  Verret et al.[@B14] (2005)             102/NA                     Craniofacial                  Norian CRS, Mimix, Bone Source   3.5 yr           4           \-                                 6                       \-                        \-           1
  Zins et al.[@B25] (2007)               16/35 yr                   Craniofacial                  Norian CRS, Bone Source          3 yr             3           \-                                 \-                      8                         \-           \-
  Gosain et al.[@B21] (2009)             8/5.5 yr                   Cranial                       Norian CRS, Bone Source          5.7 yr           1           \-                                 \-                      \-                        \-           \-
  Kerr et al.[@B18] (2009)               177/NA                     Transptrosal reconstruction   HA                               NA               12          12                                 \-                      3                         \-           \-
  Gilardino et al.[@B23] (2009)          46/24.9 yr                 Cranioplasty                  Norian CRS                       43.9 mo          9           3                                  \-                      \-                        \-           \-
  Singh et al.[@B24] (2010)              78/9 yr                    Craniofacial                  Mimix, Bone Source               NA               4           3                                  \-                      \-                        2            \-
  This case                              1/28 yr                    Craniofacial                  JectOS                           9 mo             \-          1                                  1                       \-                        \-           \-

(NA: not available, HA: hydroxyapatite)

Manufacturer information: Bone Source, Stryker Leibinger; Norian CRS, Synthes-Stratec; Mimix, Walter Lorenz Surgical; JectOS, Kasios.
